Discovery and development of Boceprevir, an HCV NS3 protease inhibitor, for the treatment of hepatitis C infection

被引：0
|
作者：
Howe, Anita [1 ]
机构：
[1] Merck Reserach Lab, Kenilworth, NJ 07033 USA
来源：
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY | 2012年 / 243卷
关键词：
D O I：
暂无
中图分类号：
O6 [化学];
学科分类号：
0703 ;
摘要：
365-BIOL
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Evolutionary dynamics of hepatitis C virus NS3 protease domain during and following treatment with narlaprevir, a potent NS3 protease inhibitor
    de Bruijne, J.
    Thomas, X. V.
    Rebers, S. P.
    Weegink, C. J.
    Treitel, M. A.
    Hughes, E.
    Bergmann, J. F.
    de Knegt, R. J.
    Janssen, H. L. A.
    Reesink, H. W.
    Molenkamp, R.
    Schinkel, J.
    JOURNAL OF VIRAL HEPATITIS, 2013, 20 (11) : 779 - 789
  • [22] Telaprevir: An NS3/4A Protease Inhibitor for the Treatment of Chronic Hepatitis C
    Smith, Lisa S.
    Nelson, Michael
    Naik, Sagar
    Woten, Joanna
    ANNALS OF PHARMACOTHERAPY, 2011, 45 (05) : 639 - 648
  • [23] Clinical Pharmacology Profile of Boceprevir, a Hepatitis C Virus NS3 Protease Inhibitor: Focus on Drug–Drug Interactions
    Sauzanne Khalilieh
    Hwa-Ping Feng
    Ellen G. J. Hulskotte
    Larissa A. Wenning
    Joan R. Butterton
    Clinical Pharmacokinetics, 2015, 54 : 599 - 614
  • [24] Discovery of GS-9256: A novel phosphinate HCV NS3 protease inhibitor
    Sheng, Christopher
    Clarke, Mike
    Ji, Mingzhe
    Pyun, Hyungjung
    Wu, Qiaoyin
    Cai, Ruby
    Chaudhary, Kleem
    Wang, Jianying
    Tay, Chin
    Chen, Xiaowu
    Appleby, Todd
    Pakdaman, Roshy
    Yang, Chris
    Yang, Huiling
    Robinson, Margaret
    Wang, Ruth
    Doerffler, Edward
    Liu, Xiaohong
    Barauskas, Ona
    Schultz, Brian
    Delaney, Bill
    Kim, Choung
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2011, 242
  • [25] Telaprevir: A Hepatitis C NS3/4A Protease Inhibitor
    Matthews, Samuel James
    Lancaster, Jason W.
    CLINICAL THERAPEUTICS, 2012, 34 (09) : 1857 - 1882
  • [26] SEQUENCE EVOLUTION OF THE HCV NS3/4A PROTEASE DURING ACUTE HEPATITIS C VIRUS (HCV) INFECTION
    Dietz, J.
    Lutz, T.
    Knecht, G.
    Gute, P.
    Nehring, A.
    Raziorrouh, B.
    Diepolder, H.
    Zeuzem, S.
    Sarrazin, C.
    JOURNAL OF HEPATOLOGY, 2010, 52 : S408 - S408
  • [27] Computational Modelling in Studies for Hepatitis C Virus (HCV) NS3 Protease
    Mukhametov, Azat
    CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2016, 16 (12) : 1351 - 1361
  • [28] Boceprevir: an oral protease inhibitor for the treatment of chronic HCV infection
    Trembling, Paul M.
    Tanwar, Sudeep
    Dusheiko, Geoffrey M.
    EXPERT REVIEW OF ANTI-INFECTIVE THERAPY, 2012, 10 (03) : 269 - 279
  • [29] GRAZOPREVIR POTASSIUM HCV NS3 NS4A protease inhibitor Anti-hepatitis C virus drug
    Majumdar, A.
    Gilliam, B. L.
    DRUGS OF THE FUTURE, 2016, 41 (02) : 85 - 109
  • [30] Clinical Pharmacology Profile of Boceprevir, a Hepatitis C Virus NS3 Protease Inhibitor: Focus on Drug-Drug Interactions
    Khalilieh, Sauzanne
    Feng, Hwa-Ping
    Hulskotte, Ellen G. J.
    Wenning, Larissa A.
    Butterton, Joan R.
    CLINICAL PHARMACOKINETICS, 2015, 54 (06) : 599 - 614
12345